keyword
MENU ▼
Read by QxMD icon Read
search

Oral ribavirin

keyword
https://www.readbyqxmd.com/read/29664710/analysis-of-host-and-viral-related-factors-associated-to-direct-acting-antiviral-response-in-hepatitis-c-virus-patients
#1
Hafsa Aziz, Muneeba Aziz, Muzaffar Lateef Gill
Hepatitis C virus (HCV) signifies an important health issue as it is a globally prevalent pathogen and poses a great threat to human health. Direct antiviral therapy became a landmark in treatment against chronic HCV infection as they have proven to increase sustained virological response (SVR) rate, provide shortened and simplified regimens. This study aimed to evaluate efficacy of Sofosbuvir and classify factors of treatment success and their function in therapy continuation decision. We studied host and viral factors in 310 patients who received Sofosbuvir (DAA) at a dose of 400 mg daily along with ribavirin 10 mg/kg body weight for 24 weeks and followed by 12 weeks after completion of treatment...
April 2018: Viral Immunology
https://www.readbyqxmd.com/read/29663115/sofosbuvir-plus-daclatasvir-with-or-without-ribavirin-for-treatment-of-chronic-hcv-genotype-4-patients-real-life-experience
#2
G Shiha, R Soliman, M ElBasiony, A A Hassan, N N H Mikhail
INTRODUCTION: New regimens involving direct-acting antiviral agents have recently been approved for the treatment of HCV. Our aim was to assess the efficacy and safety of 12 or 24 weeks of Sofosbuvir 400 mg plus Daclatasvir 60 mg, with or without ribavirin (800-1000 mg) in treating chronic hepatitis C genotype 4 patients. METHODS: This is an open-label observational study that describes the effect of 12 week or 24 weeks of daily oral Sofosbuvir (SOF) 400 mg plus Daclatasvir (DCV) 60 mg with or without ribavirin (RBV) with dose adjustment if indicated...
April 16, 2018: Hepatology International
https://www.readbyqxmd.com/read/29628768/outcomes-and-predictors-of-treatment-response-with-sofosbuvir-plus-daclatasvir-with-or-without-ribavirin-in-egyptian-patients-with-genotype-4-hepatitis-c-virus-infection
#3
Ossama A Ahmed, Mohamed A Elsebaey, Mohamed Hassan A Fouad, Heba Elashry, Ahmed I Elshafie, Ahmed A Elhadidy, Noha E Esheba, Mohammed H Elnaggar, Shaimaa Soliman, Sherief Abd-Elsalam
Background and aims: Treatment of hepatitis C virus (HCV) changed dramatically with the introduction of oral direct-acting antiviral drugs due to their high antiviral potency and safety profile. Sofosbuvir plus daclatasvir combination therapy was extensively investigated in HCV genotypes 1, 2, and 3, while published data regarding its real-life application in the treatment of genotype 4 is lacking. Therefore, we conducted this study to assess the outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection...
2018: Infection and Drug Resistance
https://www.readbyqxmd.com/read/29596108/hepatocellular-carcinoma-after-sustained-virological-response-with-interferon-free-regimens-in-hiv-hcv-coinfected-patients
#4
Nicolás Merchante, Francisco Rodríguez-Arrondo, Boris Revollo, Esperanza Merino, Sofía Ibarra, María J Galindo, Marta Montero, Miguel García-Deltoro, Antonio Rivero-Juárez, Francisco Téllez, Marcial Delgado-Fernández, María J Ríos-Villegas, María A García, Francisco J Vera-Méndez, Guillermo Ojeda-Burgos, Miguel A López-Ruz, Luis Metola, Mohamed Omar, María Remedios Alemán-Valls, Koldo Aguirrebengoa, Joseba Portu, Miguel Raffo, Juan Macías, Juan A Pineda
OBJECTIVE: To assess the possible association between the use of direct antiviral agents (DAA) and the risk of hepatocellular carcinoma (HCC) in HIV/HCV-coinfected patients. METHODS: The GEHEP-002 cohort recruits HCC cases in HIV-infected patients from 32 centers from Spain. Three analyses were performed: the proportion of HCC cases after sustained virological response (SVR) and the evolution of this proportion over time, the frequency of HCC after SVR in HIV/HCV-coinfected patients with cirrhosis, and the probability of HCC recurrence after curative therapies among those undergoing HCV therapy...
March 28, 2018: AIDS
https://www.readbyqxmd.com/read/29595065/protease-inhibitor-therapy-for-hepatitis-c-virus-infection
#5
P de Leuw, C Stephan
The hepatitis C virus (HCV) has affected an estimated of 80 million individuals worldwide and is a strain on public health. Around 25-30% of patients in Europe and the US who are infected with HIV are coinfected with HCV. Prior to 2013, treatment modalities containing an NS3/4A protease inhibitor in combination with pegylated interferon and ribavirin improved sustained virological response (SVR) rates. However, rates of severe side effects were high. Nowadays, oral direct-acting antiviral (DAA) combination therapy offers excellent treatment efficacy, safety and tolerability...
April 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29589331/population-pharmacokinetic-analysis-of-asunaprevir-in-subjects-with-hepatitis-c-virus-infection
#6
Li Zhu, Hanbin Li, Phyllis Chan, Timothy Eley, Yash Gandhi, Marc Bifano, Mayu Osawa, Takayo Ueno, Eric Hughes, Malaz AbuTarif, Richard Bertz, Tushar Garimella
INTRODUCTION: Asunaprevir (ASV) is a potent, pangenotypic, twice-daily hepatitis C virus (HCV) NS3 inhibitor indicated for the treatment of chronic HCV infection. METHODS: A population pharmacokinetic (PPK) model was developed using pooled ASV concentration data from 1239 HCV-infected subjects who received ASV either as part of the DUAL regimen with daclatasvir or as part of the QUAD regimen with daclatasvir and peg-interferon/ribavirin. RESULTS: A two-compartment model with first-order elimination from the central compartment, an induction effect on clearance, and an absorption model consisted of zero-order release followed by first-order absorption adequately described ASV PK after oral administration...
March 27, 2018: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/29582685/-real-life-experience-with-direct-acting-antiviral-agents-for-hepatitis-c-virus-in-end-stage-renal-disease
#7
Rebeca García-Agudo, Sami Aoufi-Rabih, Mercedes Salgueira-Lazo, Carmen González-Corvillo, Fabrizio Fabrizi
BACKGROUND AND AIMS: The advent of direct-acting antiviral agents promises to change the management of hepatitis C in patients with end-stage renal disease, a patient group where the treatment of hepatitis C was historically challenging. We investigated the safety and efficacy of all-oral, interferon-free direct-acting antiviral agents for the treatment of hepatitis C in a 'real-world' group of patients with end-stage renal disease. METHODS: We performed a single-arm, multi-centre study in a cohort (n=30) of patients with advanced chronic kidney disease (mostly on dialysis) who underwent antiviral therapy with direct-acting antiviral agents...
March 1, 2018: International Journal of Artificial Organs
https://www.readbyqxmd.com/read/29566611/treatment-of-hcv-in-the-department-of-corrections-in-the-era-of-oral-medications
#8
Richard K Sterling, Reena Cherian, Shawn Lewis, Kathleen Genther, Carolyn Driscoll, Kelly Martin, Mary Beth Goode, Scott Matherly, Mohammad S Siddiqui, Velimir A Luketic, R Todd Stravitz, Puneet Puri, Hannah Lee, Paula Smith, Vaishali Patel, Arun J Sanyal
Chronic hepatitis C virus (HCV) is widely prevalent in the Virginia Department of Corrections (DOC). However, sustained virologic response (SVR) with all oral direct-acting antiviral (DAA) therapy is unknown. HCV treatment was provided through telemedicine following guidelines of the American Association for the Study of Liver Diseases and Infectious Diseases Society of America. SVR12 in the DOC was compared in two control groups: privately insured and indigent patients receiving care in HCV treatment clinics by the same providers during the same time period...
January 1, 2018: Journal of Correctional Health Care
https://www.readbyqxmd.com/read/29557529/clinical-pharmacokinetics-and-drug-drug-interactions-of-elbasvir-grazoprevir
#9
Tony K L Kiang
Elbasvir and grazoprevir, in a fixed-dose combination of 50 and 100 mg, respectively, have received approval to be administered orally once daily, with or without ribavirin, for the treatment of chronic hepatitis C virus (HCV) infections. The absorption characteristics of elbasvir and grazoprevir have been adequately summarized, although differences were observed for grazoprevir (e.g., increased exposure at steady state in patients), but not elbasvir, between healthy and HCV-infected subjects. Inconsistencies with respect to absorption were also reported on the effects of food or acid reducers (famotidine or pantoprazole) in the literature...
March 20, 2018: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/29546644/retreatment-efficacy-of-sofosbuvir-ombitasvir-paritaprevir-ritonavir-ribavirin-for-hepatitis-c-virus-genotype-4-patients
#10
Adel Abdel-Moneim, Alaa Aboud, Mohamed Abdel-Gabbar, Mohamed Zanaty, Mohamed Ramadan
BACKGROUND: The current standard of care for patients with chronic hepatitis C virus (HCV) infection is a combination of direct-acting antiviral agents (DAAs). However, rare clinical trials have been reported on the combination regimen of sofosbuvir (SOF) with ombitasvir, paritaprevir, and ritonavir (OBV/PTV/r) plus ribavirin (RBV) for treated patients with HCV genotype 4 (GT4) infection. AIMS: To clarify the retreatment efficacy and safety of the recent regimen, SOF with OBV/PTV/r + RBV, for chronic HCV GT4-experienced patients who failed treatment with DAA-based regimens...
May 2018: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/29535545/efficacy-and-safety-of-sofosbuvir-ledipasvir-for-treatment-of-a-cohort-of-egyptian-patients-with-chronic-hepatitis-c-genotype-4-infection
#11
Ossama A Ahmed, Hany H Kaisar, Rehab Badawi, Nehad Hawash, Hossam Samir, Sherif St Shabana, Mohamed Hassan A Fouad, Fatma H Rizk, Samy A Khodeir, Sherief Abd-Elsalam
Background and aims: Treatment of hepatitis C virus (HCV) infection has significantly changed during the last few years. The combination of ledipasvir and sofosbuvir has been shown to treat high proportions of patients with HCV genotype 1 with remarkable tolerability. The aim of the work was to assess the efficacy and safety of sofosbuvir plus ledipasvir in treating treatment-naïve Egyptian patients with genotype 4 HCV infection. Patients and methods: In this open-label randomized study, 200 treatment-naive patients who were HCV antibody positive and HCV RNA positive by polymerase chain reaction, aged >18 years, were enrolled...
2018: Infection and Drug Resistance
https://www.readbyqxmd.com/read/29457839/brincidofovir-as-salvage-therapy-for-adenovirus-disease-in-intestinal-transplant-recipients
#12
Nimisha Sulejmani, Shunji Nagai, Mohamed Safwan, Michael D Rizzari, Mohammad Raoufi, Marwan S Abouljoud, Mayur Ramesh
BACKGROUND: Adenoviruses are double-stranded DNA viruses that typically cause mild self-limiting respiratory, ocular, and gastrointestinal infections. In immunocompromised patients, especially transplant recipients, the infection can be severe, with dissemination and multiorgan failure. In intestinal transplant recipients, the incidence is as high as 57%. To our knowledge, no standardized guidelines or U.S. Food and Drug Administration-approved medications exist for the treatment of adenovirus disease...
April 2018: Pharmacotherapy
https://www.readbyqxmd.com/read/29417462/chronic-hepatitis-c-in-elderly-patients-current-evidence-with-direct-acting-antivirals
#13
REVIEW
Manan A Jhaveri, Vignan Manne, Kris V Kowdley
Since the introduction of direct-acting antivirals (DAAs), the outcomes of hepatitis C (HCV) treatment have shown an improvement in cure rates with minimal side effects. However, to date, the safety and efficacy of DAAs have not been specifically examined in elderly patients. The treatment of HCV in the era of pegylated interferon and ribavirin was more challenging among elderly patients due to the increased prevalence of multiple comorbid conditions associated with an increased risk of side effects, including anemia, and high rates of discontinuation, likely as a result of poor tolerability, resulting in lower rates of sustained virologic response (SVR)...
February 7, 2018: Drugs & Aging
https://www.readbyqxmd.com/read/29404508/sofosbuvir-induced-steven-johnson-syndrome-in-a-patient-with-hepatitis-c-virus-related-cirrhosis
#14
Nipun Verma, Shreya Singh, Gitesh Sawatkar, Virendra Singh
Sofosbuvir is an imperative drug used in treatment regimens for hepatitis C virus (HCV). It is considered relatively safe with fewer adverse effects than other treatments. Here, we report a rare and potentially serious, dermatologic, adverse effect following the use of sofosbuvir. A 35-year-old man with genotype 3-related HCV cirrhosis presented with decompensated ascites and jaundice following 7 weeks of therapy with peginterferon alpha-2a and oral ribavirin. After peginterferon withdrawal and stabilization, oral sofosbuvir and ribavirin were started; 10 days later, he developed itching over the trunk and legs, followed by multiple papules and vesicles over an erythematous base...
January 2018: Hepatology Communications
https://www.readbyqxmd.com/read/29380288/ledipasvir-sofosbuvir-a-review-in-chronic-hepatitis-c
#15
Lesley J Scott
Oral once-daily, fixed-dose, ledipasvir/sofosbuvir (Harvoni® ) [± ribavirin] is approved in several countries for the treatment of chronic hepatitis C (CHC) in adults and adolescents aged 12 to < 18 years, with direct-acting antiviral (DAA) regimens resulting in a paradigm shift in the treatment of the disease. In the clinical trial and/or clinical practice setting, ledipasvir/sofosbuvir (± ribavirin) was associated with high sustained virological response rates 12 weeks post-treatment (SVR12) in treatment-naive and -experienced adults and adolescents with chronic hepatitis C virus (HCV) genotype (GT) 1 infection, including in those with compensated cirrhosis or who were co-infected with HIV...
February 2018: Drugs
https://www.readbyqxmd.com/read/29377464/efficacy-of-generic-oral-directly-acting-agents-in-patients-with-hepatitis-c-virus-infection
#16
S Gupta, G Rout, A H Patel, M Mahanta, N Kalra, P Sahu, R Sethia, A Agarwal, G Ranjan, S Kedia, S K Acharya, B Nayak, Shalimar
Novel direct-acting antivirals (DAAs) are now the standard of care for the management of hepatitis C virus (HCV) infection. Branded DAAs are associated with high sustained virological response at 12 weeks post-completion of therapy (SVR12), but are costly. We aimed to assess the efficacy of generic oral DAAs in a real-life clinical scenario. Consecutive patients with known HCV infection who were treated with generic-oral DAA regimens (May 2015 to January 2017) were included. Demographic details, prior therapy and SVR12 were documented...
January 28, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29377274/all-oral-daa-therapy-against-hcv-in-hiv-hcv-coinfected-subjects-in-real-world-practice-madrid-core-findings
#17
Juan Berenguer, Ángela Gil-Martin, Inmaculada Jarrin, Ana Moreno, Lourdes Dominguez, Marisa Montes, Teresa Aldámiz-Echevarría, María J Téllez, Ignacio Santos, Laura Benitez, José Sanz, Pablo Ryan, Gabriel Gaspar, Beatriz Alvarez, Juan E Losa, Rafael Torres-Perea, Carlos Barros, Juan V San Martin, Sari Arponen, María Teresa de Guzmán, Raquel Monsalvo, Ana Vegas, María T Garcia-Benayas, Regino Serrano, Luis Gotuzzo, María Antonia Menendez, Luis M Belda, Eduardo Malmierca, María J Calvo, Encarnación Cruz-Martos, Juan J González-García
We evaluated treatment outcomes in a prospective registry of HIV/HCV-coinfected patients treated with interferon-free direct-acting antiviral agent (DAA)-based therapy in hospitals from the region of Madrid between November 2014 and August 2016. We assessed sustained viral response (SVR) at 12 weeks after completion of treatment and used multivariable logistic regression to identify predictors of treatment failure. We evaluated 2,369 patients, of whom 59.5% were non-cirrhotic (Non-C), 33.9% had compensated cirrhosis (Co-C), and 6...
January 29, 2018: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29360277/comparative-effectiveness-of-aerosolized-versus-oral-ribavirin-for-the-treatment-of-respiratory-syncytial-virus-infections-a-single-center-retrospective-cohort-study-and-review-of-the-literature
#18
Tracy P Trang, Meghan Whalen, Alexandra Hilts-Horeczko, Sarah B Doernberg, Catherine Liu
BACKGROUND: Respiratory syncytial virus (RSV) is a leading cause of viral infections in immunocompromised hosts and is associated with significant morbidity and mortality. In January 2015, our institution switched from aerosolized to oral ribavirin (RBV) for primary treatment of RSV infection among high-risk immunocompromised adult patients. The objective of the study was to evaluate the clinical and economic outcomes associated with this switch. METHODS: Retrospective cohort analysis of adult patients diagnosed with RSV infection and treated with RBV between January 1, 2013, and May 31, 2016...
April 2018: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29346834/twelve-week-ravidasvir-plus-ritonavir-boosted-danoprevir-and-ribavirin-for-non-cirrhotic-hcv-genotype-1-patients-a-phase-2-study
#19
Jia-Horng Kao, Min-Lung Yu, Chi-Yi Chen, Cheng-Yuan Peng, Ming-Yao Chen, Huoling Tang, Qiaoqiao Chen, Jinzi J Wu
BACKGROUND AND AIM: The need for all-oral hepatitis C virus (HCV) treatments with higher response rates, improved tolerability, and lower pill burden compared with interferon-inclusive regimen has led to the development of new direct-acting antiviral agents. Ravidasvir (RDV) is a second-generation, pan-genotypic NS5A inhibitor with high barrier to resistance. The aim of this phase 2 study (EVEREST study) was to assess the efficacy and safety of interferon-free, 12-week RDV plus ritonavir-boosted danoprevir (DNVr) and ribavirin (RBV) regimen for treatment-naïve Asian HCV genotype 1 (GT1) patients without cirrhosis...
January 18, 2018: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29327780/systematic-review-with-meta-analysis-effectiveness-and-tolerability-of-interferon-free-direct-acting-antiviral-regimens-for-chronic-hepatitis-c-genotype-1-in-routine-clinical-practice-in-asia
#20
REVIEW
F Ji, B Wei, Y H Yeo, E Ogawa, B Zou, C D Stave, Z Li, S Dang, N Furusyo, R C Cheung, M H Nguyen
BACKGROUND: Direct-acting antiviral (DAA) regimens have shown high efficacy and tolerability for patients with HCV genotype 1/1b (GT1/1b) in clinical trials. However, robust real-world evidence of interferon (IFN)-free DAA treatment for HCV GT1-infected patients in Asia is still lacking. AIM: To systematically review and meta-analyse the effectiveness and tolerability of IFN-free DAA therapy for HCV GT1 infection in Asia. METHODS: We included studies that enrolled adult patients with HCV GT1 infection in routine clinical practice in Asia, using IFN-free DAA regimens, and reported sustained virological response (SVR) after 12/24 weeks end-of-treatment by 31 May 2017...
March 2018: Alimentary Pharmacology & Therapeutics
keyword
keyword
89557
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"